Your browser doesn't support javascript.
loading
Resveratrol inhibits nonalcoholic fatty liver disease in rats.
Bujanda, Luis; Hijona, Elizabeth; Larzabal, Mikel; Beraza, Marta; Aldazabal, Pablo; García-Urkia, Nerea; Sarasqueta, Cristina; Cosme, Angel; Irastorza, Belen; González, Alberto; Arenas, Juan I.
  • Bujanda L; Department of Gastroenterology, University of Country Basque, Donostia Hospital, Centro de Investigación Biomédica en Enfermedades Hepáticas y Digestivas, San Sebastián, Spain. medik@telefonica.net
BMC Gastroenterol ; 8: 40, 2008 Sep 09.
Article en En | MEDLINE | ID: mdl-18782455
BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in tumor necrosis factor alpha (TNF-alpha) production, lipid peroxidation and oxidative stress. METHODS: Male Wistar CRL: Wi (Han) (225 g) rats were randomized into three groups. A control group (n = 12) was given free access to regular dry rat chow for 4 weeks. The steatosis (n = 12) and resveratrol (n = 12) groups were given free access to feed (a high carbohydrate-fat free modified diet) and water 4 days per week, and fasted for the remaining 3 days for 4 weeks. Rats in the resveratrol group were given resveratrol 10 mg daily by the oral route. All rats were killed at 4 weeks and assessed for fatty infiltration and bacterial translocation. Levels of TNF-alpha in serum, hepatic malondialdehyde (MDA), oxidative stress (superoxide dismutase, glutathione peroxidase, catalase and nitric oxide synthase) and biochemical parameters were measured. RESULTS: Fat deposition was decreased in the resveratrol group as compared to the steatosis group (Grade 1 vs Grade 3, P < 0.05). TNF-alpha and MDA levels were significantly increased in the steatosis group (TNF-alpha; 33.4 +/- 5.2 vs 26.24 +/- 3.47 pg/ml and MDA; 9.08 +/- 0.8 vs 3.17 +/- 1.45 muM respectively, P < 0.05). This was accompanied by increased superoxide dismutase, glutathione peroxidase and catalase and decreased nitric oxide synthase in the liver of resveratrol group significantly (P < 0.05 vs steatosis group). Bacterial translocation was not found in any of the groups. Glucose levels were decreased in the group of rats given resveratrol (P < 0.05). CONCLUSION: Resveratrol decreased NAFLD severity in rats. This effect was mediated, at least in part, by TNF-alpha inhibition and antioxidant activities.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Estilbenos / Hígado Graso / Antioxidantes Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Año: 2008 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Estilbenos / Hígado Graso / Antioxidantes Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Año: 2008 Tipo del documento: Article